FN2 Earnings Intelligence
Quest Diagnostics Incorporated financials
Quest Diagnostics Incorporated (DGX) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $872 | $315 | $686 | $549 | $420 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $10,788 | $9,883 | $9,252 | $9,872 | $11,035 | $11,959.1 | $12,510.4 |
| % Growth | 14.3% | -8.4% | -6.4% | 6.7% | 11.8% | 8.4% | 4.6% |
| Gross Profit | $4,209 | $3,433 | $3,053 | $3,244 | $3,665 | - | - |
| % Margin | 39.0% | 34.7% | 33.0% | 32.9% | 33.2% | - | - |
| EBITDA | $2,789 | $1,865 | $1,701 | $1,839 | $2,126 | - | - |
| % Margin | 25.9% | 18.9% | 18.4% | 18.6% | 19.3% | - | - |
| Net Income | $1,995 | $946 | $854 | $871 | $992 | - | - |
| % Margin | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% | - | - |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 | $11.07 | $11.94 |
| % Growth | 48.5% | -48.7% | -6.0% | 2.7% | 13.8% | 26.5% | 7.8% |
| Operating Cash Flow | $2,233 | $1,718 | $1,272 | $1,334 | $1,886 | - | - |
| CapEx | $403 | $404 | $408 | $425 | $527 | - | - |
| Free Cash Flow | $1,830 | $1,314 | $864 | $909 | $1,359 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $10,788 | $9,883 | $9,252 | $9,872 | $11,035 | $11,959.1 | $12,510.4 |
| Gross Profit | $4,209 | $3,433 | $3,053 | $3,244 | $3,665 | - | - |
| EBITDA | $2,789 | $1,865 | $1,701 | $1,839 | $2,126 | - | - |
| Net Income | $1,995 | $946 | $854 | $871 | $992 | - | - |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 | $11.07 | $11.94 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $872 | $315 | $686 | $549 | $420 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $4,010 | $3,978 | $4,410 | $5,615 | $5,167 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2,233 | $1,718 | $1,272 | $1,334 | $1,886 |
| Capital Expenditure | $403 | $404 | $408 | $425 | $527 |
| Free Cash Flow | $1,830 | $1,314 | $864 | $909 | $1,359 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 14.3% | -8.4% | -6.4% | 6.7% | 11.8% |
| Gross Margin | 39.0% | 34.7% | 33.0% | 32.9% | 33.2% |
| EBITDA Margin | 25.9% | 18.9% | 18.4% | 18.6% | 19.3% |
| Net Margin | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
| FCF Margin | 17.0% | 13.3% | 9.3% | 9.2% | 12.3% |
| Diluted EPS Growth | 48.5% | -48.7% | -6.0% | 2.7% | 13.8% |